

Remarks

Claims 1-15 are pending in the application. The claims were amended in the international phase, as set forth in the Annex to the International Preliminary Examination Report. Claim 1 is as set forth in the Annex. Claims 2-15 have been further amended as set forth herein to reduce dependencies and more closely conform to United States practice.

Respectfully submitted,

CAMILO ANTHONY LEO SELWYN COLACO



DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Phone: (215) 988-3312
Fax: (215) 988-2757
Attorney for Applicant

APPENDIX A: Mark-up of amended claims

2. (amended) The [A] method as claimed in claim 1, wherein [characterised in that] the active ingredient of the immunogenic determinant [consists] predominantly comprises [of] one or more shock protein/antigenic peptide fragment complexes.
3. (amended) The [A] method as claimed in claim 1, wherein [either of claims 1 or 2, characterised in that] the stress-inducing stimulus is heat.
4. (amended) The [A] method as claimed in claim 3, wherein [claim 3, characterised in that] the pathogenic organism is heated to from 5 to 8°C above the normal temperature for cultivation of the organism.
5. (amended) The [A] method as claimed in claim 1, wherein [any of one of the preceding claims, characterised in that] the pathogenic organism is an extra-cellular prokaryotic or protozoan species.
6. (amended) The [A] method as claimed in claim 1, wherein [any of one of the preceding claims, characterised in that] the pathogenic organism is a bacterial, protozoal or fungal species.
7. (amended) The [A] method as claimed in claim 1, wherein [any of one of the preceding claims, characterised in that] the immunogenic determinant is a mixture of heat shock protein/antigenic peptide fragment complexes.
8. (amended) The [A] method as claimed in claim 1, wherein [any of one of the preceding claims, characterised in that] the extra-cellular pathogenic organism has been modified to induce or enhance the induction of the synthesis of stress proteins.
9. (amended) The [A] method as claimed in claim 1, wherein [any of one of the preceding claims, characterised in that it] the method is carried out in vitro.
10. (amended) A vaccine composition [containing] comprising an immunogenic determinant, [characterised in that] wherein the immunogenic determinant comprises one

APPENDIX A: Mark-up of amended claims

or more complexes between a heat shock protein and an antigenic peptide fragment derived from the heat treatment of an extra-cellular pathogenic organism.

11. (amended) A vaccine composition produced by the method of claim 1 [any one of claims 1 to 9].

12. (amended) A vaccine composition as claimed in claim 10, wherein [either of claims 10 or 11, characterised in that] the composition [also contains] comprises an adjuvant for the immunogenic determinant.

13. (amended) The [A] vaccine composition as claimed in [any one of claims 10 to 12, characterised in that it] claim 10, which is an aqueous composition.

14. (amended) A method for treating an animal with a vaccine [, characterised in that it comprises] comprising administering a pharmaceutically acceptable quantity of a vaccine composition as claimed in [any one of claims 10 to 13] claim 10, sufficient to elicit an immune response in the animal.

15. (amended) A method for eliciting an immune response from an animal infection by an intra-cellular pathogenic organism the method comprising [the steps of;]:

administering a vaccine containing an immunogenic determinant, the immunogenic determinant being a stress protein/antigenic peptide fragment complex produced in situ from the intra-cellular pathogen, the synthesis of the complex being induced by external stress stimuli or by genetic modification of the pathogen so as to render its synthesis constitutive.

